Collagen breakdown products as markers of fibrosis and cirrhosis.

Collagen breakdown products as markers of fibrosis and cirrhosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Collagen breakdown products as markers of fibrosis and cirrhosis. Abstract Text:

Collagens are extracellular matrix proteins that maintain the structural integrity of various tissues. Because normal collagen contained in connective tissues and bone is known to undergo metabolic alterations in a wide variety of diseases, there has been a great deal of interest in how measurements of protein fragments derived from collagen biosynthesis and breakdown could be used as markers of pathological collagen turnover. Immunological assays are now available for several proteins representing genetically distinct collagen types. Some of these, like the aminoterminal propeptide of type III procollagen (PIIINP), have reached a level where the measurements are part of normal routine in the treatment and assessment of patients with conditions involving excessive fibrogenesis. To date, PIIINP appears to be superior to the other markers available in terms of sensitivity and informative value for a clinician. New developments in this field may yield methods by which increased rates of collagen biosynthesis can be differentiated from collagen breakdown. Moreover, increasing knowledge on the endothelial cell function may open new avenues with respect to the interpretation of the assay results.

Collagen breakdown products as markers of fibrosis and cirrhosis. Publishing Authors By Initials

For similar proteins: protein precursors: procollagen research abstracts see: proteins: protein precursors: procollagen research

PUBMED ID PMID:

MEDLINE DATE:

Collagen breakdown products as markers of fibrosis and cirrhosis. Journal Published:

PUBLICATION TYPE: Review

Journal: Alcohol and alcoholism (Oxford, Oxfordshire). Supp

VOLUME: 2

Page Numbers: 345-52

Journal Abbreviation:

ISSN: 1358-6173

DAY: 26

MONTH: 02

YEAR: 1994

Collagen breakdown products as markers of fibrosis and cirrhosis. Information

Number of References: 85

LANGUAGE: eng

NlmUniqueID: 8804836

Collagen breakdown products as markers of fibrosis and cirrhosis. Keywords Mesh Terms:

KEYWORDS: Procollagen

MESH TERMS: metabolism

Chemical & Substance for Abstract: Collagen breakdown products as markers of fibrosis and cirrhosis. Information

Substance Name: Collagen

Registry Number: 9007-34-5

Grant and Affiliation Information for Collagen breakdown products as markers of fibrosis and cirrhosis.

AFFILIATION: Department of Clinical Chemistry, University of Helsinki, EP Central Hospital Laboratory, Seinäjoki, Finland.

Country: ENGLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Alcohol Alcohol Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Collagen breakdown products as markers of fibrosis and cirrhosis Related Publications

• Acetaldehyde adducts in circulation.
• Biodegradable coating for drug-eluting stents--more than a facelift?
• Co-occurrence of IgA antibodies against ethanol metabolites and tissue transglutaminase in alcohol consumers: correlation with proinflammatory cytokines and markers of fibrogenesis.
• Collagen breakdown products as markers of fibrosis and cirrhosis.
• Commentary.
• Duodenogastric reflux in patients with upper abdominal complaints or gastric ulcer with particular reference to reflux-associated gastritis.
• Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index.
• Gender-related differences in the management of non-ST-elevation acute coronary syndrome patients.
• Historical landmarks in vascular neurosurgery "On July 10th 2006, at the 70th Anniversary of the Department of Neurosurgery of Zürich Medical School".
• Homogeneous TR-FRET high-throughput screening assay for calcium-dependent multimerization of sorcin.
• Microsurgical treatment of third ventricular colloid cysts by interhemispheric far lateral transcallosal approach-experience of 134 patients.
• Response.
• Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
• [In Process Citation]